Reply to: How carvedilol does not activate β2-adrenoceptors

• Evi Kostenis,
• Jesus Gomeza,
• Elke Miess-Tanneberg,
• Nina Kathleen Blum,
• Tobias Benkel,
• Andy Chevigné,
• Carsten Hoffmann,
• Peter Kolb,
• Viacheslav Nikolaev,
• Maria Waldhoer,
• Martyna Szpakowska,
• Asuka Inoue,
• Stefan Schulz

Affiliations

Evi Kostenis

Molecular, Cellular, and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn

Jesus Gomeza

Molecular, Cellular, and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn

Elke Miess-Tanneberg

Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich-Schiller-University of Jena

Nina Kathleen Blum

Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich-Schiller-University of Jena

Tobias Benkel

Molecular, Cellular, and Pharmacobiology Section, Institute of Pharmaceutical Biology, University of Bonn

Andy Chevigné

Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH)

Carsten Hoffmann

Institute for Molecular Cell Biology, CMB-Center for Molecular Biomedicine, Jena University Hospital, Friedrich Schiller University of Jena

Peter Kolb

Department of Pharmaceutical Chemistry, Philipps-University of Marburg

Viacheslav Nikolaev

Institute of Experimental Cardiovascular Research, University Medical Center Hamburg-Eppendorf

Maria Waldhoer

InterAx Biotech AG

Martyna Szpakowska

Immuno-Pharmacology and Interactomics, Department of Infection and Immunity, Luxembourg Institute of Health (LIH)

Asuka Inoue

Graduate School of Pharmaceutical Science, Tohoku University

Stefan Schulz

Institute of Pharmacology and Toxicology, Jena University Hospital, Friedrich-Schiller-University of Jena